[Cell source Co., Ltd.]
Launched the first overcounter sales at major drug store Tomoz, a leading online drug “Signalift” from Regenerative Medicine Center

Cell Source Corporation Launched the first over-the-counter sales at major drug store Tomoz, a leading drug store “Signalift” from Regenerative Medicine Center From July 26th, Tomozu limited trial set simultaneous sale- ………………………………………………………………………………………… Cellsource Co., Ltd., a regenerative medicine-related business, developed its own skincare cosmetics “Signalift” series, and at Tomos Co., Ltd., a major drug store “Tomozu” that develops stores on a nationwide scale July 26, 2019 We will start selling from (Fri). In addition, to commemorate this, Tomozu limited “trial set” will be released simultaneously. In addition, we will carry out a campaign where you can purchase products at a 20% off price. The Signalift series is a product exclusively for Internet mail order, and this will be the first effort to expand in actual stores.
[Image 1


[Image 2

Cellsource Co., Ltd. (Head office: Shibuya-ku, Tokyo; President and CEO: Masato Enomoto, below: our company), which develops regenerative medicine-related businesses, shares in the self-developed skin care cosmetic “Signalift” series. Company Tomods (Head office: Bunkyo-ku, Tokyo; President: Hideyuki Tokushima, hereinafter “Tomos Co., Ltd.”) Tomorrow, a major drug store with stores nationwide on a nationwide scale: 168 stores ※ 1 at July 1, 2019 We will start selling from 26th (Fri). In addition, to commemorate this, Tomozu limited “Trial Set” will be released at the same time, bundled with a full lineup of beauty essences, creams and cleansers. In addition, we will carry out a campaign where you can purchase products at a 20% off price. In addition, our skin care cosmetics are products exclusively for the Internet mail order, and this is the first effort to expand in actual stores. We are engaged in the business of providing consignment services for culture and processing of adipose-derived stem cells used in regenerative medicine for medical institutions. The Signalift series was developed based on the concept of “defying the common sense of skin care” based on the research on adipose-derived stem cells at the regenerative medicine center, which is the base of our business. The greatest feature is the high concentration of the unique component “Signa-Peptide (R)”, which was developed focusing on the mechanism by which skin firmness is generated. This is the effect of aging care * 2 It exerts and leads to beautiful and youthful skin. This time, Tomozu Co., Ltd.’s management policy to propose products that satisfy customers sincerely, and those who were not satisfied with conventional skin care, and many who are considering a new aging care * 2 approach As our desire to get the product in hand was in agreement, we decided to launch in-store sales. We will continue to promote our business for the safe and prompt diffusion of regenerative medicine, and hope to return the accumulated research results to many people in the form of active utilization for products. You Please refer to the attached sheet attached to PDF (https://prtimes.jp/a/?f=d24685-20190719-393.pdf) or the official site (https://www.signalift.com) for the product details of the Signalift series. Please give me. The trial sets and campaign details to start selling in the store limited are as follows.
[Tomos limited aging care ※ 2 trial set (for 3 days)]
We will release a trial set exclusively for the store, so that you can feel free to try the Signalift series.
[Image 3

Price: 1,296 yen (tax included) Contents of trial set: ・ Jelly wash (gel pack cleansing) 6 packets ・ Extra-enriched (high-performance beauty essence) 6 packets ・ Enriched cream (high performance moisturizing cream) 6 packets
【campaign】
For a limited time, we will carry out a special campaign to sell the SIGNA LIFT series products at a 20% off price in the store. ・ Campaign period: July 26, 2019-Friday, September 30, 2019 -Target product and sales price after campaign application (tax included)
[Table 2: https://prtimes.jp/data/corp/24685/table/17_1.jpg”>

that’s all * 1 The total number of drug store brands (Tomos, American Pharmacy, Inclover, Katsuma) operated by Tomozu Co., Ltd. (excluding dispensing specialty stores). As of July 19, 2019 ※ 2 Care according to age Press Release Details PDF (https://prtimes.jp/a/?f=d24685-20190719-393.pdf)
【Tomos Co., Ltd.】
Based on the management philosophy of “Aiming to be a family pharmacy that contributes to the well-being and well-being of customers as a retailer responsible for medical treatment,” Tomos develops 168 stores mainly in Tokyo, Kanagawa Prefecture and Saitama Prefecture. We continue to create attractive stores as an urban drug store. ○ Head office location: 15-15, Nishikata 1-chome, Bunkyo-ku, Tokyo KDX Kasuga Building 3F Representative representative: President and CEO Hideyuki Tokushima ◯ Establishment: September 1993 Home page: https://www.tomods.jp/
【Cell Source Corporation】
With the aim of promoting the industrialization of regenerative medicine, we are developing legal support services for medical institutions aiming to start providing regenerative medicine and a contract processing business for processing cells and the like. Currently, we are entrusted with processing of more than 7,000 cells and tissues in a specified cell product manufacturing permission facility (facility number: FA3160006) based on the Safety Assurance Act for Regenerative Medicine, etc. We strive to provide services that institutions can use with confidence, and research and technology development. ○ Head office location: 1-19-5 Shibuya, Shibuya-ku, Tokyo Shibuya Mitake Building 2F ◯ Representative: President and CEO Masato Tsubakimoto (Masato Tsumamoto) ◯ Capital: 90 million yen ◯ Establishment: November 30, 2015 Home page: https://www.cellsource.co.jp


For more information about this release(Japanese):
https://prtimes.jp/main/html/rd/p/000000017.000024685.html https://prtimes.jp